0.8616
Precedente Chiudi:
$0.8049
Aprire:
$0.8
Volume 24 ore:
4.95M
Relative Volume:
0.74
Capitalizzazione di mercato:
$53.41M
Reddito:
-
Utile/perdita netta:
$-22.83M
Rapporto P/E:
-1.0906
EPS:
-0.79
Flusso di cassa netto:
$-20.87M
1 W Prestazione:
+26.71%
1M Prestazione:
+187.20%
6M Prestazione:
+14.29%
1 anno Prestazione:
-53.17%
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Nome
Cognition Therapeutics Inc
Settore
Industria
Telefono
412-481-2210
Indirizzo
2403 SIDNEY STREET, PITTSBURGH
Confronta CGTX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
CGTX
Cognition Therapeutics Inc
|
0.8616 | 48.06M | 0 | -22.83M | -20.87M | -0.79 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-19 | Aggiornamento | B. Riley Securities | Neutral → Buy |
2024-07-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2021-11-03 | Iniziato | B. Riley Securities | Buy |
2021-11-03 | Iniziato | Oppenheimer | Outperform |
Cognition Therapeutics Inc Borsa (CGTX) Ultime notizie
Cognition Therapeutics Inc. Stock Analysis and ForecastExceptional risk-adjusted gains - PrintWeekIndia
What analysts say about Cognition Therapeutics Inc. stockFree Bull & Bear Market Updates - Autocar Professional
What drives Cognition Therapeutics Inc. stock priceBreakneck growth rates - Autocar Professional
Is Cognition Therapeutics Inc. a good long term investmentFree Predictions - jammulinksnews.com
Cognition Therapeutics Publishes Proteomic Analysis - GlobeNewswire
Cognition Therapeutics reports positive results for Alzheimer’s drug - Investing.com India
Cognition Therapeutics Publishes Phase 2 Study Results of Zervimesine for Alzheimer's Disease in Alzheimer's & Dementia Journal - Nasdaq
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease - The Manila Times
Breakthrough: New Alzheimer's Drug Protects Brain Cells from Death, Phase 2 Study Reveals - Stock Titan
How high can Cognition Therapeutics Inc. stock price go in 2025Capital Efficient Investment Tips - beatles.ru
Dementia Associated with Alzheimer’s Disease Drug - GlobeNewswire
Lewy Body Dementia Market Set to Grow Substantially Through - openPR.com
Cognition Therapeutics stock soars after DLB study results - Investing.com
Cognition Therapeutics stock soars after DLB study results By Investing.com - Investing.com Nigeria
CGTX Soars 19.72% on Promising Dementia Drug Results - AInvest
Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies - Nasdaq
Cognition Therapeutics' Positive Clinical Data from - GlobeNewswire
Breakthrough DLB Treatment: Clinical Trial Reveals 86% Symptom Improvement in Dementia Patients - Stock Titan
Cognition Enhancing Drugs Market CAGR 5.6 % innovations and key - openPR.com
How Cognition Therapeutics Inc. stock performs during market volatilityMomentum Buy Alert - Newser
Why Cognition Therapeutics Inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - Newser
What makes Cognition Therapeutics Inc. stock price move sharplyFree High-Profit Stock Picks - Newser
Cognition Therapeutics shares fall 1.16% premarket after Karolinska Development's portfolio company Umecrine Cognition raises SEK 24.6 million for clinical development. - AInvest
CGTX’s 2025 Market Saga: Unraveling the Story of Gains and Losses - investchronicle.com
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Rating of “Buy” from Analysts - Defense World
Cognition Therapeutics (NASDAQ:CGTX) Rating Lowered to Strong Sell at Wall Street Zen - Defense World
Cognition Therapeutics: Clinical Milestones Ignite Potential in Neurodegenerative Therapeutics - AInvest
Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress - Yahoo Finance
Cognition Therapeutics, Inc. (CGTX) Plunges 14.29% Amid FDA Meeting Outcome - AInvest
Cognition Therapeutics shares fall 10.57% in premarket after FDA meeting on zervimesine for Alzheimer's treatment. - AInvest
Cognition Therapeutics Inc Azioni (CGTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):